New IRAK4 inhibitor to fight inflammation-driven ovarian cancer spread and resistance
Official title: Development of EDI-239382, a novel IRAK4 inhibitor to control inflammation driven metastasis, immune dysfunction and chemoresistance niche in ovarian tumors.
Funded at Edi Therapeutics LLC · NIH-11311782 · Data updated 2026-11-12
A new oral drug candidate called EDI-238382 targets a key inflammatory pathway to slow ovarian cancer growth, spread, and resistance to chemotherapy in a preclinical model.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Edi Therapeutics LLC NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $377,537 |
| NIH project number | 1R43CA309899-01 |
| Project ID | NIH-11311782 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with high-grade serous ovarian cancer or individuals at risk of metastasis who could participate in future translational studies or trials.
✕Less likely to help
Patients without ovarian cancer or without a role in future trials targeting IL-1/IRAK4 pathways may not benefit.
What this research studies
This program focuses on a novel IRAK4 inhibitor designed to interrupt the IL-1/TLR signaling that may drive ovarian cancer progression. Researchers will study how the drug behaves in the body (ADMET) and whether it can shrink tumors and improve chemotherapy response in a mouse model that mimics human high-grade serous ovarian cancer. The work builds on previous chemistry campaigns to create a potent, orally available compound and tests its safety and anti-tumor activity. If successful, this could lay the groundwork for future clinical testing in patients with ovarian cancer.
Why it matters
Potential benefit: If effective, patients could benefit from a new therapy that reduces tumor growth and makes chemotherapy more effective.
How similar studies have gone: Similar IRAK4-targeted approaches have shown promise in preclinical cancer models, supporting further development, though clinical results are still needed.
Where this research is happening
-
Edi Therapeutics LLC
Rochester, United States Active
Researchers
- Principal investigator: Graham, Martin — Edi Therapeutics LLC
- Study coordinator: Graham, Martin
Related research
Other NIH-funded projects on the same topics.
-
Lymph node metastasis and immune tolerance in head and neck cancer
A study in people with head and neck cancer looks at how cancer spread to lymph nodes may shape the immune system and help tumors grow.
-
Targeting how RMS cells fail to mature to slow or stop pediatric muscle cancer spread
A project to understand why a pediatric muscle cancer called rhabdomyosarcoma spreads, and to test ideas that could slow or stop it by helping cancer cells mature properly.
-
Centers studying how cancer spreads through the body
A multi-institutional project at Rockefeller University is exploring how nerves, blood vessels, lymphatics, immune cells, and metabolites influence the spread of cancer to help identify new ways to stop metastasis.
-
Angiopoietin-2 and Tie2 signals shaping liver metastasis in pancreatic neuroendocrine tumors
A study explores how Angiopoietin-2 and the Tie2 receptor influence the spread of pancreatic neuroendocrine tumors to the liver and how this affects responses to immunotherapy.
-
Nanoparticles that boost MRI to find tiny brain metastases
This uses tiny magnetic nanoparticles and new MRI image processing to help doctors find very small brain metastases earlier in people with cancer.
-
Tumor-Niche Co-evolution in Ovarian Cancer Metastasis and Resistance
This research explores how ovarian cancer cells interact with their surrounding tissue to understand how metastasis and resistance to therapy develop, with potential to guide better treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.